Abstract Although solid tumors continuously shed cells, only a small fraction of the neoplastic cells that enter the blood stream are capable of establishing metastases. In order to be successful, these cells must attach, extravasate, proliferate and induce angiogenesis. Preclinical studies have shown that small-molecule ATP-competitive Src kinase inhibitors can effectively impair metastasis-associated tumor cell functions in vitro. However, the impact of these agents on the metastatic cascade in vivo is less well understood. In the present studies, we have examined the ability of saracatinib, a dual-specific, orally available inhibitor of Src and Abl protein tyrosine kinases, to interfere with the establishment of lung metastases in mice by tumor cells introduced into the blood stream. The results demonstrate that Src inhibition most effectively interferes with the establishment of secondary tumor deposits when treatments are administered while tumor cells are in the initial phases of dissemination.
Introduction
The ability of cancer cells to disseminate and form new foci of growth represents not only the most malignant characteristic of cancer but also the most common reason for the failure of conventional anticancer therapies. Indeed, metastatic disease is estimated to be the direct or indirect cause of nearly 90% of all deaths attributable to malignancy (Coghlin and Murray 2010; Sleeman and Steeg 2010; Wittekind and Neid 2005) . Nevertheless, metastases are relatively rare events, in part, because, in order to establish progressive growth at a secondary site, tumor cells must successfully navigate a complicated multi-step process that requires them to escape the primary tumor, survive in the blood stream, invade, proliferate and induce angiogenesis. Thus, the very complexity of the metastatic cascade also offers the possibility for strategic interventions targeting key signal transduction pathways associated with the functional characteristics of the metastatic phenotype.
One such target might be the Src family of non-receptor protein tyrosine kinases (Martin 2001; Summy and Gallick 2003) . Src plays a critical role in a variety of cellular signal transduction pathways associated with cell proliferation and survival (Basu and Cline 1995; Frame 2002; Taylor and Shalloway 1996; Wei et al. 2004) . Its expression also promotes tumor cell detachment, migration and invasion through the regulation of focal adhesions (Parsons and Parsons 1997; Timpson et al. 2001 ) and interaction with integrins (Playford and Schaller 2004) and proteolytic enzymes (Hauck et al. 2002; Hiscox et al. 2006; Pongchairerk et al. 2005) . In addition, Src expression has been associated with the angiogenic process, having been shown capable of modulating the expression of pro-angiogenic factors (Eliceiri et al. 1999; Ellis et al. 1998; Marx et al. 2001) , vascular permeability (Park et al. 2007 ) and tube formation (Kilarski et al. 2003; Kumar et al. 2003) .
In patients, Src is frequently over-expressed in malignancies (Egan et al. 1999; Irby and Yeatman 2000; Lutz et al. 1998; Yeatman 2004) . Furthermore, elevated Src expression or Src pathway activation might be related to poor prognosis, tumor progression and metastasis (Aligayer et al. 2002; Cartwright et al. 1994; Dehm and Bonham 2004) . Based on these observations, the inhibition of Src kinase activity has been identified as a novel anticancer treatment strategy Hiscox and Nicholson 2008) and leading agents, namely dasatinib, saracatinib and bosutinib, are currently in clinical development in a number of solid tumor settings (Aleshin and Finn 2010; Haura et al. 2010; Koppikar et al. 2008; Lara et al. 2009; Lee and Gautschi 2006; Saad and Lipton 2010; Yu et al. 2009 ).
Target validation studies including Src transfection (Myoui et al. 2003; Rucci et al. 2006) , antisense Src constructs (Wiener et al. 1999) and Src mutation studies (Boyer et al. 2002) support the role of Src as a key molecule in the metastatic cascade of cancer cells (Fizazi 2007; Saad and Lipton 2010) . Furthermore, tissue culture studies have convincingly demonstrated that clinically advanced Src targeting agents not only significantly inhibit Src signaling in a variety of tumor cell lines but also severely impair metastasis-associated tumor cell functions (Dong et al. 2010; Purnell et al. 2009; Rice et al. 2011; Schweppe et al. 2009 ). However, the impact of these small molecule Src inhibitors on the metastatic cascade in vivo is by no means as well documented. Preclinical studies of bladder ) and head and neck (Ammer et al. 2009 ) tumor models have shown that saracatinib treatment impairs lymph node metastasis, as is also the case for prostate cancer xenografts treated with dasatinib (Park et al. 2008) . In terms of the hematogenous spread of cancer cells, bosutinib treatment of a murine breast cancer model reduces the number of liver, spleen and lung metastases (Jallal et al. 2007) . Dasatinib inhibits the metastasis of human pancreatic adenocarcinoma in a nude mouse model (Trevino et al. 2006) but not the development of pulmonary metastases in a model of osteosarcoma (Hingorani et al. 2009 ). Thus, not only a paucity of in vivo data exists but a full understanding of the way that Src-signaling inhibition by these agents perturbs the metastatic cascade in situ is lacking. The goal of the present study has been to identify the phase of the blood borne dissemination of tumor cells that is impacted by Src inhibition.
Materials and methods
Src kinase inhibitor Stock solutions (10 mM) of saracatinib (AZD0530, AstraZeneca, Macclesfield, UK) were prepared by suspending the agent in 10% (v/v) Tween-80 and HEPES. Working dilutions were made by serial dilution of the stock solution in sterile saline. Saracatinib (10-25 mg/kg) was administered by oral gavage. For in vitro studies, saracatinib was dissolved in dimethylsufoxide (DMSO; 10 μM) and diluted in phosphate-buffered saline immediately prior to use, such that the DMSO exposure in cell cultures was <0.1%. All chemical reagents were purchased from Sigma (St. Louis, Mo., USA) unless otherwise indicated.
Cell lines Murine KHT sarcoma cells, received from Stanford University, Palo Alto, Calif., USA (Kallman 1967) , were grown in alpha minimal essential medium (α-MEM) supplemented with 10% fetal bovine serum (FBS) and 2 mmol/l Lglutamine (Invitrogen, Carlsbad, Calif., USA). Human microvascular endothelial cells of the lung (HMVEC-L; Lonza Biologics, Walkersville, Md., USA) were grown in EBM-2-MV media (Lonza) supplemented with 5% FBS.
Tumor cell attachment Control (0.1% DMSO) or saracatinib (0.5, 2.5, or 5 μM) pretreated KHT sarcoma cells (1×10 6 ) were added to a monolayer of endothelial (HMVEC-L) cells. After 2 h, the number of tumor cells remaining unattached in the supernatant was counted.
Endothelial cell migration HMVEC-L (5×10
2 ) were either pretreated with saracatinib (0-10 μM) for 24 h prior to seeding them into modified Boyden-chambers (BD Biosciences, Palo Alto, Calif., USA) or exposed to the agent during the 24-h assessment period. Cells remaining on top of the 8-μm-pore membrane were then removed by using cotton swabs. Migrated cells on the other side of the membrane were fixed, stained with crystal violet and counted at 5× magnification.
Tube formation HMVEC-L (6×10 4 ) plated in triplicate were either pre-treated with 0-10 μM saracatinib (for 24 or 48 h) or exposed to saracatinib after them being plated on Matrigel pre-coated 24-well plates (BD Biosciences, Palo Alto, Calif., USA) to assess tube formation. The cells were incubated for 24-72 h at 37°C and tube formation was observed and photographed.
Supernatant levels of vascular endothelial growth factor KHT sarcoma cells (1.6×10 6 ) were seeded in 60-mm dishes and then treated with 0-10 μM saracatinib for a period of 24 h. Supernatants were collected and the concentrations of vascular endothelial growth factor (VEGF) in the media were determined by enzyme-linked immunosorbent assay according to the manufacturer's protocol (R&D Systems. Minneapolis, Minn., USA).
Intra-dermal angiogenesis assay Six-to eight-week-old female nude mice (Jackson Laboratories, Bar Harbor, Me., USA) were injected intra-dermally with 1×10
5 KHT sarcoma cells in four ventral locations (3 mice/group). Cells were either treated with saracatinib (0-5 μM) prior to injection or mice were treated with daily doses of saracatinib (0-10 mg/kg) after tumor cell inoculation. In either case, the mice were killed 3 days later, the skin containing the four nodules was removed and the number of blood vessels that intersected the tumor cell nodules was counted by using a dissection microscope.
Artificial lung metastases KHT sarcoma cells (2-5×10 3 ) were injected via the tail vein in a volume of 0.2 ml saline (10 mice/group). Animals were killed 21 days later and their lungs were collected. The number of metastatic foci formed in the lungs were counted by using a dissecting microscope. The sizes of individual lung nodules were measured by using a scaled eyepiece accessory of the microscope.
Statistics Statistical significance was determined by using a Wilcoxon rank sum test. For all analyses, P<0.05 was considered to be significant.
Animals All research was governed by the principles of the Guide for the Care and Use of Laboratory Animals (USPHS) and was approved by the University of Florida Institutional Animal Care and Use Committee (Gainesville, Fla., USA). Mice were maintained in a specific pathogenfree environment (University of Florida Health Science Center, Gainesville, Fla., USA), with food and water being provided ad libitum.
Results
Saracatinib is a highly selective, orally available small molecule that can inhibit Src kinase activity by interfering with Src phosphorylation at tyrosine 419-human/423-mouse (Hennequin et al. 2006 ). In the highly metastatic KHT sarcoma model, Src kinase inhibition by saracatinib results in significant impairment of metastasis-associated tumor cell functions (Dong et al. 2010) .
To determine whether saracatinib could impair the ability of KHT sarcoma cells to establish secondary tumor growth in situ, tumor cells were injected into the blood stream via the tail vein (on day 0), mice were treated with the Src inhibitor (at various times post tumor cell inoculation) and the number of metastatic foci formed in the lungs was determined 21 days later. In initial studies, the mice were treated with daily 10-or 25-mg/kg doses of saracatinib beginning at 1 day post tumor cell inoculation (Fig. 1) . The results showed that such treatments led to significant reductions (P<0.05, Wilcoxon rank sum test) in the number of lung colonies formed, both saracatinib doses being equally effective (Fig. 1a) . For example, the 10-and 25-mg/kg doses resulted in 53%/47% and 60%/31% reductions in the number of lung colonies formed compared with those detected in mice receiving only the drug carrier. The median size of the lung foci detected did not differ significantly between saracatinib-treated mice and drug-carriertreated control animals (Fig. 1b) .
Three additional experiments were conducted with the treatment protocol consisting in daily 10-mg/kg doses of saracatinib administered on days 1-20 after introduction of the tumor cells into the blood stream (Fig. 2a) . The results confirmed the reduction of approximately two-fold in lung colonies in saracatinib-treated mice shown in Fig 1a. A second protocol, in which the number of 10-mg/kg saracatinib doses was halved and the agent was administered only on days 3-7 and 10-14, also significantly reduced the number of neoplastic cell lung foci (Fig. 2b) but less effectively Fig. 1 Median number (a) and sizes (b) of neoplastic cell foci in the lungs of mice determined 21 days after intravenous injection of KHT sarcoma cells. Beginning the day after cell injection, the mice were treated daily with either the drug carrier or saracatinib (10 or 25 mg/ kg). Bars and hatched areas represent 90% and 75% confidence intervals, respectively (stars statistical significance at P<0.05 [Wilcoxon's rank-sum test] compared with controls) (35% versus 50% reduction in lung colony formation). The efficacy of the latter treatment protocol was primarily attributable to the initial five doses of saracatinib, since (1) the treatment of mice with this agent only on days 3-7 (Fig. 3a,  b) was as effective at reducing lung colony formation (25 and 42% reduction) as was the treatment on days 3-7 plus on days 10-14 and (2) treatment only on days 10-14 failed to affect the number of lung colonies formed (Fig. 3a) . Furthermore, five doses of saracatinib administered in the final days of lung colony growth (days 17-21) also had no effect on the resultant number of lung colonies (Fig. 3b) .
Our initial results (Figs. 1, 2, 3 ) implied that the exposure of mice to the Src inhibitor soon after the intravenous introduction of tumor cells had the greatest impact on the subsequent establishment of secondary site tumor growth. To examine this possibility further, mice injected with tumor cells were treated with one of three daily 10-mg/kg saracatinib protocols (Fig. 4 ). These were: (1) a single dose of saracatinib administered immediately (within 1 h) after tumor cell injection (day 0), (2) 4 doses of the agent given on days 0-3 and (3) 21 drug doses administered over the entire course of the experiment. Three independent studies were conducted and the results showed that the three treatment protocols were equally effective at significantly reducing the ability of KHT sarcoma cells to form lung colonies.
Previous in vitro investigations in our laboratory had shown that the treatment of KHT sarcoma cells with saracatinib inhibited Src and FAK activation and tumor cell migration and invasion (Dong et al. 2010) . Another function of tumor cells that contributes to the in vivo metastatic process is attachment. To study the interaction between KHT tumor cells and endothelial cells, drug-treated and control tumor cells were added to a monolayer of endothelial cells. The results (Fig. 5) showed that saracatinib pretreatment significantly affected the ability of KHT tumor cells to attach to endothelial cells, i.e., the number of tumor cells that failed to attach to endothelial cells increased in a dose-dependent manner. For example, during the 2-h assessment period, more than twice as many tumor cells in the group pretreated with 5 μM saracatinib remained unattached as compared with tumor cells in the untreated control group (Fig. 5) .
Once established at a new site, progressive tumor growth requires the initiation of angiogenesis (Siemann and Horsman 2009) . Src has been shown to play a role in this process (Eliceiri et al. 1999; Ellis et al. 1998; Kilarski et al. 2003; Marx et al. 2001; Park et al. 2007 ) and consequently a component of the antitumor effects associated with Src inhibitors might be attributed to their anti-angiogenic action (Fizazi 2007; Saad and Lipton 2010) . To study this possibility, the impact of saracatinib treatment on endothelial cell function was investigated in vitro. At the molecular level, a 24-h exposure to saracatinib decreased pSrc in HMVEC-L cells in a dose-dependent manner in the absence of changes in Src expression (Fig. 6a) . However, these doses of saracatinib (1-10 μM) did not affect HMVEC-L growth (data not shown) or migration (Fig. 6f) . Furthermore, pretreatment of HMVEC-L with saracatinib for 24 or 48 h prior to an assessment of their ability to form tubes or exposure of the cells to the agent during the tube formation period (24-48 h) had no effect on the ability of HMVEC-L to form tubes ( Fig. 6b-e) . Established endothelial tubes were also unaffected by saracatinib treatments of up to 72 h (data not shown). A 24-h saracatinib exposure did however significantly reduce VEGF secretion by KHT sarcoma cells (Fig. 6g) .
To study the effect of saracatinib treatment on angiogenesis induced by KHT sarcoma cells in vivo, an intradermal assay was used (Shi and Siemann 2002) . Two treatment strategies were employed: tumor cells were either pretreated with non-cytotoxic doses of saracatinib (1 or 5 μM; Dong et al. 2010 ) prior to injection, or the mice were treated with daily doses of saracatinib (10 or 25 mg/kg) beginning immediately after tumor cell injection. In both cases, the mice were killed 3 days later, the skin flap containing the inoculation site was excised and the number of blood vessels induced was counted. The results (Fig. 7) showed that, compared with controls, KHT tumor cells that were pretreated with saracatinib induced significantly fewer blood vessels (Fig. 7a) . Similarly, skin flaps from mice treated with saracatinib also showed significant reductions in the number of blood vessels induced by KHT sarcoma cells (Fig. 7b) .
Discussion
Src kinases are a family of non-receptor tyrosine kinases that act as signal-transduction modulators and are a critical component of many of the key signaling pathways pivotal in cancer progression (Dehm and Bonham 2004; Frame 2002; Lutz et al. 1998; Summy and Gallick 2003) . Src mediates signaling from several receptors and the downstream effects of Src kinase signaling influence cell growth, proliferation, invasion and apoptosis (Frame 2002) . In particular, increased Src kinase signaling activity ultimately promotes an invasive tumor cell phenotype. In patients, elevated Src kinase activity has been documented in several tumor types (Aligayer et al. 2002; Dehm and Bonham 2004; Lutz et al. 1998 ) as being associated with tumor progression and linked to poor prognosis (Aligayer et al. 2002; Cartwright et al. 1994; Dehm and Bonham 2004) . As a consequence, Src kinase inhibition has been suggested to hold a significant therapeutic potential as an anti-metastatic therapy for solid tumors (Aleshin and Finn 2010; Green et al. 2009; Hiscox and Nicholson 2008; Irby and Yeatman 2000; Saad and Lipton 2010; Summy and Gallick 2003) . However, in the discussion of anti-metastatic therapies, we need to differentiate therapies that affect the progression of established secondary site neoplastic foci from interventions that impair the process of neoplastic cell dissemination.
In bone metastases, tumor cells dysregulate the normally balanced activities of osteoclasts and osteoblasts resulting in significant morbidity (Coleman et al. 2001; Mundy 2002) . Src signaling is a key pathway involved in enhancing osteoclast activity and maintaining the osteoblast pre-differentiation state (Miyazaki et al. 2004; Yoneda and Hiraga 2005) . Src therefore represents a logical target for the treatment of advanced metastatic prostate or breast cancer (Fizazi 2007; Saad and Lipton 2010) . In support of this, preclinical studies have shown that both dasatinib and saracatinib affect tumor growth in bone; a likely consequence not only of the antineoplastic cell activities of the agents but also of their inhibitory effects on osteoclastmediated bone resorption, which plays a significant role in the growth and expansion of bone neoplastic lesions (de Vries et al. 2009; Yang et al. 2010) . Furthermore, two recent clinical studies have shown that saracatinib inhibits bone resorption (Hannon et al. 2010 (Hannon et al. , 2012 .
The focus of the present investigation has been to assess the impact of saracatinib treatment on the ability of tumor Fig. 5 Number of non-adherent KHT sarcoma cells remaining in the supernatant 2 h after 1×10 6 tumor cells were added to a monolayer of endothelial cells. Tumor cells were pretreated with 0.1% dimethylsulfoxide (control) or saracatinib (0.5, 2.5, or 5 μM) for 24 h prior to their addition to the endothelial cells. After 2 h, the number of tumor cells remaining unattached in the supernatant was counted. Data are the mean number (±SE) of cells in 6-well plates in three experiments (stars statistical significance at P<0.05 versus control) Fig. 6 Effect of a 24-h exposure of saracatinib (1-10 μM) on HMVEC-L Src and Src phosphorylation (a; C control), tube formation (b-e) and motility (f). Bars 100 μm (b-e). The level of vascular endothelial growth factor (VEGF) determined in the media of KHT sarcoma cells after a 24-h saracatinib treatment is shown in g. Data are the results (mean±SE) from three independent experiments (stars statistical significance at P<0.05 versus control) cells to establish secondary lesions after entering the blood stream. We have previously reported that KHT sarcoma cells pretreated with non-cytotoxic/non-cytostatic doses of saracatinib display a reduced ability to establish neoplastic lung lesions when injected intravenously (Dong et al. 2010) . We have subsequently observed that this result is not limited to the KHT tumor model or the Src inhibitor saracatinib as we have noted a similar outcome for 4T1 breast carcinoma cells pretreated with dasatinib (Saffran and Siemann 2011) , i.e., non-toxic doses of a Src inhibitor readily impair the ability breast cancer cells to form pulmonary lesions.
The present studies indicate that the in situ saracatinib treatment of mice bearing blood-borne tumor cells exerts its primary effect on the development of pulmonary metastases rather than impairing the progression of established metastatic foci. Several lines of evidence support this conclusion. Initial studies in which mice have been treated with daily doses of 10 or 25 mg/kg saracatinib beginning the day after intravenous tumor cell injection and lasting throughout the assessment period have shown that both treatments lead to a significant decrease in the number of lung colonies formed (Fig. 1a) . However, the size of the neoplastic lesions formed in the treated and control mice are not significantly different (Fig. 1b) indicating that the primary therapeutic effect of the saracatinib treatment is a consequence of a reduction in the number of tumor cells capable of forming lung colonies. Moreover, the lack of a significant difference in efficacy between the two treatment groups (Fig. 1a) suggests that Src inhibition alone is not sufficient to block the development of lung metastases completely and implies that further increases in the dose of saracatinib will have little additional therapeutic benefit.
To gain additional support for the notion that the targeting of Src signaling predominantly affects the early stages of tumor cell dissemination, we have undertaken a series of experiments utilizing a variety of in situ treatment schedules (Figs. 2, 3, 4) . The results show that the timing of the administration of the Src inhibitor is far more critical to its ability to impair the metastatic cascade than the total dose. For example, a reduction in the number of daily 10-mg/kg saracatinib doses from 20 to 10 has little impact on its efficacy (Fig. 2) . Furthermore, a comparison of the results illustrated in Figs. 2, 3 makes it readily apparent that saracatinib treatments administered during the first week after intravenous injection of tumor cells are responsible for the observed reduction in the number of pulmonary tumor nodules, with treatments commencing on day 10 or 14 failing to have a significant effect. Perhaps most intriguingly, a single dose of the Src inhibitor administered shortly after the tumor cells are introduced into the circulation is as effective at inhibiting the establishment of tumors in the lungs as any of the other treatment schedules investigated.
These findings suggest that those tumor cells undergoing extravasation (attachment, invasion, migration) are particularly vulnerable to saracatinib therapy. In support of this, in vitro studies have shown that saracatinib doses that are nontoxic and non-cytostatic significantly inhibit KHT sarcoma cell migration and invasion (Dong et al. 2010) and their attachment to endothelial cells (Fig. 5) . The lack of a measurable response to saracatinib treatment in established lung tumor nodules (≥ 10 days after intravenous injection) is consistent with our finding that the treatment of mice bearing 200 mg primary KHT tumors with 10 or 25 mg/kg saracatinib has no effect on the growth rate of these tumors (data not shown). The latter result is in keeping with the reports of others of the modest antitumor effects of Src inhibitors. In the case of saracatinib, neither bladder cancer ) nor head and neck squamous cell carcinoma (Ammer et al. 2009 ) xenograft growth is significantly inhibited when such xenografts are treated with saracatinib, whereas only a subset of human pancreatic xenografts responded to this agent (Rajeshkumar et al. 2009 ). Similarly, dasatinib has also shown only limited efficacy against solid tumors in preclinical investigations (Hingorani et al. 2009 ).
Interestingly, the lack of tumor growth inhibition occurs despite evidence that small-molecule ATP-competitive Src kinase inhibitors can suppress angiogenesis (Eliceiri et al. 1999; Ellis et al. 1998; Kilarski et al. 2003; Park et al. 2007 ). In the present investigation, saracatinib treatment (1-10 μM) suppresses Src phosphorylation in endothelial cells (Fig. 6a) but does not affect endothelial cell tube formation (Fig. 6b-e) or migration (Fig. 6f) . However, the secretion of VEGF by KHT sarcoma cells is significantly reduced (Fig. 6g) . Furthermore, the treatment of both saracatinib-pretreated KHT cells and mice bearing KHT sarcoma cells with saracatinib demonstrates clear evidence of an in vivo antiangiogenic effect of saracatinib (Fig. 7) . Thus, the antiangiogenic effects of saracatinib might contribute to early phases of lung nodule development but these are clearly not sufficient to impact the growth of established lung colonies.
Because aberrant Src signaling has been linked to cancer cell functions associated with an enhanced metastatic phenotype, Src inhibitors are being actively pursued for their potential as anti-metastatic anticancer agents. As such Srcsignaling interventions could prove efficacious against secondary disease or impact the spread of neoplastic cells from a primary tumor, a therapeutic distinction often blurred in experimental investigations of such agents. Nevertheless, a clearer understanding and a better distinction of the way that Src inhibitors impact the metastatic cascade and/or established metastases could have a significant impact on the clinical settings in which to apply such agents. The present studies have been undertaken to investigate whether molecular intervention in Src-associated signaling by saracatinib can reduce the hematogenous spread of KHT sarcoma cells. In particular, these studies have sought to determine which stage in the process of establishing viable progressive secondary tumor growth is the most susceptible to Src inhibitor therapy. The results have demonstrated that the exposure of mice to saracatinib while tumor cells are in the "extravasation and establishment of new growth" phases of the metastatic process is therapeutically the most beneficial.
